INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 174 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $281,000 | -21.7% | 17,258 | -21.7% | 0.04% | -15.6% |
| Q4 2021 | $359,000 | -69.4% | 22,035 | -72.2% | 0.04% | -62.5% |
| Q3 2021 | $1,175,000 | +145.8% | 79,145 | +999.4% | 0.12% | +84.6% |
| Q3 2019 | $478,000 | -34.6% | 7,199 | -42.8% | 0.06% | +30.0% |
| Q3 2017 | $731,000 | +3.4% | 12,596 | +195.3% | 0.05% | +42.9% |
| Q3 2015 | $707,000 | +173.0% | 4,265 | +296.7% | 0.04% | +250.0% |
| Q2 2015 | $259,000 | -94.4% | 1,075 | -94.5% | 0.01% | -95.9% |
| Q3 2014 | $4,595,000 | +437.4% | 19,412 | +437.0% | 0.24% | +520.5% |
| Q2 2014 | $855,000 | -26.6% | 3,615 | +2.3% | 0.04% | -53.0% |
| Q1 2014 | $1,165,000 | – | 3,534 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |